Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)
3.490
+0.030 (0.87%)
Feb 3, 2026, 3:00 PM CST
SHA:600664 Revenue
Harbin Pharmaceutical Group had revenue of 3.90B CNY in the quarter ending September 30, 2025, a decrease of -5.29%. This brings the company's revenue in the last twelve months to 15.94B, down -1.72% year-over-year. In the year 2024, Harbin Pharmaceutical Group had annual revenue of 16.18B with 4.65% growth.
Revenue (ttm)
15.94B
Revenue Growth
-1.72%
P/S Ratio
0.55
Revenue / Employee
1.57M
Employees
10,180
Market Cap
8.79B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.18B | 719.28M | 4.65% |
| Dec 31, 2023 | 15.46B | 1.65B | 11.93% |
| Dec 31, 2022 | 13.81B | 1.01B | 7.86% |
| Dec 31, 2021 | 12.80B | 2.01B | 18.66% |
| Dec 31, 2020 | 10.79B | -1.04B | -8.76% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| KPC Pharmaceuticals,Inc. | 7.35B |
| China Animal Husbandry Industry | 6.28B |
| Zhejiang Xianju Pharmaceutical | 3.59B |
| Tianjin Ringpu Bio-Technology | 3.37B |
| Zhejiang Tianyu Pharmaceutical | 2.99B |
| Guilin Sanjin Pharmaceutical | 2.08B |
| Hubei Hongyuan Pharmaceutical Technology | 1.77B |
| Hainan Haiyao | 825.66M |